 Shares of Alterity Therapeutics Ltd. nearly tripled up 173 toward a 3-year high on heavy volume in premarket trading Tuesday, after the therapeutic drugs developer said it will present positive data for its lead drug candidate ATH434 for the treatment of multiple system atrophy MSA, a Parkinsonian disorder. Trading volume ballooned to 8.3 million shares, already more than double the full-day average of 3.5 million shares. The company said new animal data confirm and extend previous finding that demonstrated ATH434 reduced pathology, preserved neurons and improved motor performance. The company said it has been selected to present at the 2020 International Congress of Parkinsons Disease and Movement Disorders, and the American Neurological Associations 2020 Annual Meeting. Alterity said it will also present cardiac safety data from its Phase 1 study of ATH434. The stock has run up 73.1 year to date through Monday, while the SP 500 has gained 2.0. 